JERUSALEM, May 19, 2022 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present in person at the HC Wainwright Global Investment Conference, the May 24, 2022 in Miami, Florida.
The presentation, which will be given by the President of BiondVax, Mr. Marc Germainon tuesday 24 mayeat9:30 a.m. ET, will focus on BiondVax’s development of innovative nanoscale antibodies (NanoAbs) that have significant competitive advantages over existing therapies. NanoAbs are developed in collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen, Germanyto treat diseases with high unmet medical needs and exciting business opportunities such as COVID-19, asthma, psoriasis, psoriatic arthritis and macular degeneration.
Any investors in attendance who would like to meet Mr. Germain at the conference are encouraged to contact Investor Relations by email using the contact details listed below.
Further information on the conference is available at https://hcwevents.com/globalconference.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and marketing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, the company has completed eight clinical trials, including a phase 3 trial in seven countries and 12,400 participants of its candidate vaccine and has built a state-of-the-art manufacturing facility for biopharmaceuticals. With highly experienced leadership in the pharmaceutical industry, BiondVax aims to develop a pipeline of diverse and commercially viable products and platforms, starting with an innovative nanoscale antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.
Company: Joshua E. Phillipson | +972 8 930 2529 | [email protected]
Investor Relations: kenny green | +1 212 378 8040 | [email protected]
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect”, “believe”, “intend”, “plan”, “continue” , “may”, “will”, “anticipate” and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial condition, future revenues, projected expenditures, outlook, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding conference attendance, the timing of future clinical trials, the therapeutic and commercial potential of NanoAbs, and the execution of a definitive amendment agreement with the EIB. These forward-looking statements reflect management’s current beliefs regarding certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the risk that the therapeutic and commercial potential of NanoAbs will not be realized; the risk of delay of preclinical and clinical data of the NanoAbs, if any; the risk that BiondVax and the EIB fail to reach an agreement on the restructuring of the European Investment Bank loan; the risk that BiondVax may not be able to obtain additional capital on attractive terms, if at all; the risk that the European Investment Bank may accelerate lending under its financing agreement with BiondVax; risks related to the COVID-19 (coronavirus) pandemic; BiondVax’s ability to acquire rights to additional product opportunities; BiondVax’s ability to enter into collaborations on terms acceptable to BiondVax or not at all; time of receipt of regulatory approval of BiondVax’s manufacturing facility in Jerusalem, as appropriate or required; the risk that the manufacturing facility cannot be used for a wide variety of applications and other vaccine and treatment technologies, and the risk that drug development will involve a long and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2022. BiondVax undertakes no obligation to revise or update any forward-looking statement for any reason.
SOURCE BiondVax Pharmaceuticals Ltd.